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Introduction: The reported mortality rates range from 28% to 100% in burn patients who develop acute kidney
injury (AKI) and from 50% to 100% among such patients treated with renal replacement therapy. Recently, the
serum cystatin C and plasma and urine neutrophil gelatinase-associated lipocalin (NGAL) levels have been
introduced as early biomarkers for AKI; the levels of these biomarkers are known to increase 24 to 48 hours
before the serum creatinine levels increase. In this study, we aimed to estimate the diagnostic utility of the
cystatin C and plasma and urine NGAL levels in the early post-burn period as biomarkers for predicting AKI
and mortality in patients with major burn injuries.
Methods: From May 2011 to July 2012, 90 consecutive patients with a burn wound area comprising ≥ 20%
of the total body surface area (TBSA) were enrolled in this study. Whole blood and urine samples were obtained for
measuring the serum creatinine, serum cystatin C, and urine and plasma NGAL levels at 0, 3, 6, 12, 24, and 48 hours
after admission. Receiver operating characteristic curve, area under the curve, and multivariate logistic regression
analyses were performed to assess the predictive values of these biomarkers for AKI and mortality.
Results: In the multivariate logistic regression analysis, all variables, including age, percentage TBSA burned, sex,
inhalation injury, and serum creatinine levels, serum cystatin C levels, and plasma and urine NGAL levels were
independently associated with AKI development. Moreover, age, sex, percentage TBSA burned, and plasma and urine
NGAL levels were independently associated with mortality. However, inhalation injury and the serum creatinine and
cystatin C levels were not independently associated with mortality.
Conclusions: Massively burned patients who maintained high plasma and urine NGAL levels until 12 hours after
admission were at the risk of developing early AKI and early mortality with burn shock. However, the plasma and
urine NGAL levels in the early post-burn period failed to predict late AKI and non-burn shock mortality in this
study. Nevertheless, the plasma and urine NGAL levels were independently associated with AKI development
and mortality within 48 hours after admission.* Correspondence: hskim0901@empas.com
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The reported incidence rates of acute kidney injury (AKI)
among burn patients range from <1 to 36%, depending
on the population studied and the classification criteria
used [1]. The reported mortality rates among burn pa-
tients who develop AKI range from 73 to 100% [2]. During
the early phase of a major burn injury, the most common
cause of AKI is ischemic organ damage from effective
hypovolemia caused by a massive systemic inflammatory
response. During the late phase of a major burn in-
jury, sepsis and nephrotoxic agents are the most common
causes of AKI.
Laboratory research has revealed that early intervention
may be essential for preventing the pathophysiologic
events that lead to AKI. However, serum creatinine, which
is one of the main AKI biomarkers used in clinical set-
tings, is a late marker for reduced glomerular filtration
rate, which limits its use in early AKI detection and clin-
ical therapeutic studies [3]. Recently, the levels of serum
cystatin C and plasma and urine neutrophil gelatinase-
associated lipocalin (NGAL) have been suggested as early
biomarkers for AKI as their levels were found to increase
24 to 48 h prior to an increase in the serum creatinine
level [4-12].
Few studies have elucidated the associations of the serum
cystatin C, plasma NGAL, and urine NGAL levels with
AKI in patients with major burn injuries. This study had
the following aims: (1) to investigate the levels of serum
creatinine, cystatin C, and plasma and urine NGAL over
time during the early post-burn period; (2) to estimate the
diagnostic utility of the cystatin C and plasma and urine
NGAL levels for predicting AKI and mortality in patients
with major burn injuries; and (3) to determine the rela-
tionships between the levels of these biomarkers and the
burn sizes and inhalation injuries, which are known prog-
nostic factors for burn injuries.
Materials and methods
Patient selection and subgroups
From May 2011 to July 2012, 90 consecutive patients
were enrolled in this prospective cohort study. The study
protocol was approved by the Institutional Review
Boards of Hangang Sacred Heart Hospital (IRB number
2011–143), and informed consent was obtained from
all subjects. None of the patients were lost to follow
up. The inclusion criteria were as follows: patients
aged ≥18 years with % total body surface area (TBSA)
burned ≥20%. Because we intended to investigate changes
in biomarker levels during the early post-burn period, we
limited the inclusion criteria to those patients who were
admitted to our burn intensive care unit within 6 h of
injury. Patients with known cardiac disease (for example,
prior history of heart failure, arrhythmia, or coronary
heart disease), prior kidney transplant, end-stage kidneydisease, or chronic liver disease (for example, prior history
of liver cirrhosis or chronic hepatitis) were excluded. Mul-
tiple data, including sex, age, body weight, presence of co-
morbidities, % TBSA burned, % TBSA with third-degree
burn wounds, cause of burn injury, and presence of inhal-
ation injury, were collected for each patient.
AKI diagnoses were made according to the risk, injury,
failure, sustained loss, and end-stage kidney disease (RIFLE)
criteria [13]. These criteria include an increase in the serum
creatinine level ≥ 50% over the baseline or reduction in
the urine output to < 0.5 mL/kg/h for a period > 6 h. The
baseline renal function was defined as the lowest known
serum creatinine value during the preceding 3 months;
however, most of the patients had not undergone a previ-
ous laboratory evaluation. For patients without known
prior serum creatinine levels, we used the lowest serum
creatinine level measured during the admission period
only when the level was within a normal range. However,
the lowest serum creatinine levels were abnormal in six
patients. In these cases, the baseline serum creatinine
levels were estimated using the modified diet in renal dis-
ease equation for the assessment of kidney function while
assuming a glomerular filtration rate of 75 mL/minute/
1.73 m2 [13]. Considering the patients’ ages, it is possible
that we underestimated the AKI. However, all six patients
were included in the AKI group with a RIFLE stage R.
Therefore, AKI was not underestimated because of the
baseline serum creatinine levels.
As described in the Introduction, the primary cause of
AKI differs according to the time of AKI development.
Thus, we classified the patients into the following three
groups according to the time of AKI development: the
no-AKI group; the early-AKI group, wherein AKI devel-
oped within 5 days of burn injury; and the late-AKI
group, wherein AKI developed after 5 days post burn in-
jury. The mean time from burn injury to early AKI devel-
opment was 1.2 days. No patients developed AKI on day
4; however, one patient developed AKI on day 5 because
of rhabdomyolysis caused by an electrical injury. There-
fore, this patient was included in the early AKI patient
group. Thus, early AKI was considered as AKI that devel-
oped up to 5 days after burn injury.
Additionally, we classified the patients as survivors or
non-survivors according to mortality. The non-survivors
with burn shock had experienced the most severe burn
injuries, and their length of hospital stay was very short.
Therefore, we decided to divide the patient groups into
the following three groups based on the time of death: the
early-death group, the late-death group, and the survival
group. The early-death group included non-survivors who
developed burn shock despite fluid resuscitation and died
within 3 days of burn injury.
To determine whether the biomarker levels were af-
fected by the burn size or presence of inhalation injury,
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burn-size group (% TBSA burned, 20 to 49%) and larger
burn-size group (% TBSA burned, 50 to 100%).
Specimen collection and measurement of biomarkers
Blood samples were collected via a central venous catheter
and urine samples were collected via a Foley catheter, at 0,
3, 6, 12, 24, and 48 h after admission to the burn intensive
care unit. The blood NGAL levels were measured with the
Triage NGAL reagent and Triage Meter (Alere Health-
care, San Diego, CA, USA). The serum cystatin C levels
were measured according to a turbidimetric immunoassay
method with the HiSense cystatin C kit (HBi, Anyang,
Korea) and Hitachi 7600 analyzer (Hitachi, Tokyo, Japan).
The serum and urine creatinine levels were measured ac-
cording to an enzymatic method with the Cica Creatinine
reagent (KANTO Chemical, Tokyo, Japan) and Hitachi
7600 analyzer (Hitachi, Tokyo, Japan).
For the urine NGAL analysis, urine specimens were
transferred to centrifuge tubes and centrifuged at a relative
centrifugal force ≥ 400 for a minimum of 5 minutes; the
supernatants were stored at −70°C prior to batch analysis.
After thawing, the specimens were mixed and centrifuged
at 2,500 to 3,000 × g for 10 minutes prior to use, to remove
any particulate matter and ensure consistency in the re-
sults. The urine NGAL levels were measured in a chemilu-
minescence immunoassay with an Architect i2000SR
analyzer (Abbott Diagnostics, Abbott Park, IL, USA) and aTable 1 Patient characteristics according to acute kidney inju
Non-AKI (n = 35)
Age, mean ± SD 45.4 ± 14.8
Sex, male:female, n (%) 29:6 (82:18)
Mode, FB:SB:EB:CB:SKB, n (%) 27:1:4:2:1 (77:3:12:5:3)
TBSA burned, %, mean ± SD 38.4 ± 14.1
Third-degree burn wound, %, mean ± SD 24.6 ± 10.2
Inhalation injury, n (%) 4 (11.4)
Mechanical ventilation, n (%) 5 (14.3)
Rhabdomyolysis, n (%) 7 (20.0)
Early vasopressor, n (%) 1 (2.8)
Post-burn day of AKI, days, mean ± SD
CRRT, n (%)
Duration of CRRT, days, mean ± SD
Sepsis, n (%) 3 (8.6)
LOS, day, mean ± SD 55.7 ± 23.1
Mortality, n (%) 2 (5.7)
Maximal RIFLE score, n (R:I:F)
Early AKI, AKI that developed within 5 days of injury; Late AKI, AKI that developed a
chemical burn; SKB, spark burn; TBSA, total body surface area; Early vasopressor, va
renal replacement therapy; LOS, length of hospital stay; RIFLE, risk, injury, failure, sudedicated urine NGAL reagent (Abbott Diagnostics). All
measurements were performed according to the manufac-
turers’ instructions.
Data analysis
Data were expressed as mean ± SD or number (%)
for each subgroup of AKI development and mortality
(Tables 1 and 2). Statistical differences among subgroups
were analyzed using the Mann–Whitney U-test or
Kruskal-Wallis test. We investigated and compared
changes in serum creatinine, cystatin C, and plasma and
urine NGAL levels during the 48 h after admission in the
groups classified according to the time of AKI devel-
opment and mortality (Figures 1 and 2). Thereafter,
comparisons of the mean serum creatinine, cystatin C,
plasma NGAL, and urine NGAL levels at each point be-
tween patients with and without AKI and between survi-
vors and non-survivors were performed and statistically
analyzed. We also compared the changes in the levels
of these biomarkers between the groups classified ac-
cording to the burn size and inhalation injury, which are
known prognostic factors for burn injury (Figures 3
and 4). The diagnostic abilities of the plasma and urine
NGAL levels for predicting AKI and mortality were
assessed by calculating the areas under the receiver op-
erating characteristic curves (AUC-ROC) and the cut-off
value was defined by Youden’s index (Tables 3 and 4).
Multivariate analysis was performed to identify variablesry (AKI) development
AKI (n = 55) P-value
Early AKI (n = 31) Late AKI (n = 24)
51.3 ± 15.5 52.5 ± 12.4 0.129
28:3 (90:10) 20:4 (83:17) 0.641
28:1:2:0:0 (91:3:6:0:0) 20:1:1:1:1 (84:4:4:4:4)
70.7 ± 22.0 61.5 ± 19.2 <0.001
62.5 ± 28.6 48.5 ± 21.3 <0.001
17 (54.8) 8 (33.3) 0.01
28 (90.3) 19 (79.2) <0.001
24 (77.4) 4 (16.7) <0.001
21 (67.7) 3 (12.5) <0.001
1.2 ± 0.6 18.9 ± 12.1 <0.001
7 (22.6) 15 (62.5) <0.001
1.9 ± 0.7 10.9 ± 2.8 <0.001
7 (22.6) 20 (83.8) <0.001
26.6 ± 43.6 42.2 ± 35.2 0.003
24 (77.4) 14 (58.3) <0.001
0:10:21 1:5:18
fter 5 days post injury; FB, flame burn; SB, scalding burn; EB, electrical burn; CB,
sopressor infusion due to shock within 1 day of admission; CRRT, continuous
stained loss, and end-stage kidney disease; n, number of patients.
Table 2 Patient characteristics according to mortality








Age, mean ± SD 45.4 ± 14.2 54.5 ± 13.3 54.1 ± 14.5 54.3 ± 13.8 49.3 ± 13.5
Sex, male:female (%) 43:7 (86:14) 15:2 (88:12) 19:4 (83:17) 34:6 (85:15) 77:13 (86:14)
Mode, FB:SB:EB:CB:SKB (%) 40:1:5:3:1 (80:2:10:6:2) 15:1:1:0:0 (88:6:6:0:0) 20:1:1:0:1 (87:4:4:0:4) 35:2:2:0:1 (88:5:5:0:3) 75:3:7:3:2 (83:3:8:3:2)
TBSA burned, mean % ± SD 41.9 ± 15.2 82.9 ± 17.4 65.7 ± 18.4 73.0 ± 19.7 55.7 ± 23.2
Third-degree burn wound, mean % ± SD 28.0 ± 13.4 77.0 ± 24.2 54.4 ± 22.3 64.0 ± 25.5 44.0 ± 26.5
Inhalation injury, n (%) 11 (22) 13 (76.4) 5 (21.7) 18 (45) 29 (32.2)
Mechanical ventilation, n (%) 12 (24) 17 (100) 23 (100) 40 (100) 52 (57.8)
Rhabdomyolysis, n (%) 10 (20) 15 (88.2) 10 (43.4) 25 (62.5) 35 (38.9)
AKI, n (%) 17 (34) 17 (100) 21 (91) 38 (95) 55 (61.1)
Early AKI, n (%) (%) 7 (14) 17 (100) 6 (26) 23 (57.5) 31 (33.3)
Post-burn day of AKI, days, mean ± SD 14.0 ± 15.9 1.0 ± 0.0 11.2 ± 9.8 6.6 ± 8.9 9.1 ± 12.1
Cause of AKI, BS:RD:SS:MD, n 4:3:0:10 16:1:0:0 3:3:14:1 19:4:14:1 23:7:14:11
CRRT, n (%) 5 (10) 0 (0) 17 (73.9) 17 (42.5) 22 (24.4)
RIFLE (R:I:F) starting CRRT, n 0:0:5 2:8:7 2:8:7 2:8:12
Post-burn day of CRRT, days, mean ± SD 10.8 ± 7.6 14.9 ± 9.9 14.9 ± 9.9 14.0 ± 9.4
Duration of CRRT, days, mean ± SD 9.2 ± 4.4 7.0 ± 10.4 7.0 ± 10.4 7.5 ± 9.3
Early vasopressor, n (%) 1 (2) 17 (100) 7 (30.4) 24 (60) 25 (27.8)
Vasopressor, n (%) 7 (14) 17 (100) 23 (100) 40 (100) 47 (52.2)
Sepsis, n (%) 10 (20) 0 (0) 20 (86.9) 20 (50) 30 (33.3)
Cultured organism in blood (P:A:M:O:N), n 3:4:1:1:1 13:3:0:1:3 13:3:0:1:3 16:7:1:2:4
Post-burn day of sepsis, days, mean ± SD 17.5 ± 13.9 13.0 ± 8.6 13.0 ± 8.6 14.5 ± 10.6
LOS, days, mean ± SD 66.0 ± 28.2 2.5 ± 1.1 19.8 ± 15.1 12.4 ± 14.3 42.2 ± 35.2
Early deaths, non-survivors who developed burn shock in spite of fluid resuscitation and died within 3 days of burn injury; Late deaths, mortality caused by other
than burn shock; FB, flame burn; SB, scalding burn; EB, electrical burn; CB, chemical burn; SKB, spark burn; AKI: acute kidney injury; Early AKI, AKI that developed
within 5 day of injury; BS, burn shcok; RD, rhabdomyolysis; SS, septic shock; MD, medication; TBSA, total body surface area: CRRT, continuous renal replacement
therapy; RIFLE, risk, injury, failure, sustained loss, and end-stage kidney disease; RIFLE (R:I:F), patient RIFLE criteria for patients starting CRRT; Early vasopressor,
vasopressor infusion due to shock within 1 day of admission; Cultured organism: organism cultured in blood from paitents with sepsis; P: Pseudomonas aeruginosa;
A: Acinetobacter baumanii; M: multi-resistant Staphylococcus aureus; O: Other organisms; N: blood culture negative; LOS, length of hospital stay.
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tality (Table 5). SPSS 17.0 software (SPSS, Inc, Chicago,
IL, USA) was used for statistical analysis and a P-value <
0.05 was considered statistically significant.
Results
Patient characteristics
The patients’ demographic and characteristic data, classi-
fied according to AKI development, are listed in Table 1.
Of these patients, 35 did not develop AKI, 31 were classi-
fied into the early AKI group, and 24 were classified into
the late AKI group. There were 22 patients diagnosed ac-
cording to creatinine criteria alone, 2 were diagnosed ac-
cording to urinary criteria alone, and 26 were diagnosed
according to both creatinine and urinary criteria.
The sex and age were not significantly different among
the groups. However, the mean % TBSA burned, presence
of inhalation injury, mechanical ventilation, rhabdomyolysis,early vasopressor infusion, sepsis development, length of
hospital stay, and mortality differed significantly between
the groups. The early AKI group exhibited the most se-
vere burn injuries, whereas the burn injuries were more
severe in the late AKI group compared to the non-AKI
group.
Table 2 shows the patients’ demographic and characteris-
tic data classified according to mortality. There were 50 sur-
vivors and 40 non-survivors. Among the 40 non-survivors,
17 died from burn shock within 3 days of burn injury. Pa-
tients with early deaths exhibited the most severe burn in-
juries, with a mean % TBSA burned of 82.9% and a mean
length of hospital stay of only 2.5 days.
Changes in the levels of four biomarkers during 48 h
after admission with respect to AKI development
The changes in the levels of each biomarker (serum cre-
atinine, serum cystatin C, plasma NGAL, and urine NGAL)
Figure 1 Comparison of serum creatinine (a), cystatin C (b), plasma neutrophil gelatinase-associated lipocalin (NGAL) (c), and
urine NGAL (d) levels at different time points with respect to acute kidney injury (AKI) development. Early AKI, development of
AKI within 5 days of injury; Late AKI: development of AKI beyond 5 days after injury. *Significant difference (P <0.05) relative to the no
AKI group.
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At all time points, the serum creatinine and plasma and
urine NGAL levels were significantly higher in the early
AKI group than in the non-AKI group. However, the
cystatin C levels were significantly higher only at 12 and
24 h after injury when comparing the early AKI and non-
AKI groups.To estimate the predictive power of each biomarker, we
performed a ROC curve analysis for early AKI (Table 3(a)).
The significant cut-off values for serum creatinine for
predicting early AKI ranged from 0.85 to 1.15 mg/dL
between the time points of 0 and 48 h. The serum
cystatin C levels were significant only at 12 and 24 h, and
the cut-off values ranged from 0.7 to 0.75 mg/L. The
Figure 2 Comparison of serum creatinine (a), cystatin C (b), plasma neutrophil gelatinase-associated lipocalin (NGAL) (c), and urine
NGAL (d) levels at different time points with respect to mortality. Early deaths: non-survivors who developed burn shock despite fluid
resuscitation, and died within 3 days of burn injury. Late deaths: mortality due to causes other than burn shock beyond 3 days after burn injury.
*Significant difference (P <0.05) relative to the survival group.
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ranged from 100.5 to 185.5 ng/mL and the urine NGAL
cut-off values ranged from 26.8 to 52.9 ng/mL.
When we compared the non-AKI and late AKI groups
with respect to each biomarker, the serum creatinine and
cystatin C levels did not differ at any time point. However,
the plasma and urine NGAL levels differed significantlybetween the non-AKI and late AKI groups only during
the hyper-acute period (plasma NGAL: 0, 3, and 6 h after
injury; urine NGAL: 0 and 3 h after injury).
In the ROC curve analysis for predicting late AKI, only
the plasma and urine NGAL levels remained significant
for up to 6 h from injury (Table 3(b)). The cut-off values
for plasma NGAL ranged from 100.0 to 125.0 ng/mL
Figure 3 Comparison of the plasma and urine neutrophil gelatinase-associated lipocalin (NGAL) levels according to burn size and the
presence of inhalation injuries. (a, b) No inhalation injury group. (c, d) Inhalation injury group. *Significant difference (P < 0.05) between
groups. TBSA, total body surface area.
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to 11.95 ng/mL.
Changes in the levels of four biomarkers during 48 h
after admission with respect to mortality
The levels of each biomarker (serum creatinine, serum
cystatin C, plasma NGAL, and urine NGAL) were com-
pared between the groups classified according to mortal-
ity. At nearly all the time points, the serum creatinine,
plasma NGAL, and urine NGAL levels were significantly
higher in the early-death group than in the survivors
group (Figure 2). However, the cystatin C levels weresignificantly higher in the early-death group only after
12 h. In the ROC curve analysis for predicting early death,
the cut-off values for serum creatinine ranged from 0.85
to 1.65 mg/dL, those for plasma NGAL ranged from 144.5
to 191.5 ng/mL and those for urine NGAL ranged from
45.5 to 172.0 ng/mL. The cut-off values for plasma NGAL
ranged from 0.79 to 0.81 mg/L (Table 4(a)).
When we compared the late-death and survivor groups
with respect to each biomarker, no differences were found
in the serum creatinine and cystatin C levels at any time
point. Only the plasma and urine NGAL levels differed
significantly between the late death and survivor groups
Figure 4 Comparison of the plasma and urine neutrophil gelatinase-associated lipocalin (NGAL) levels according to acute kidney
injury and mortality at all time points and according to the subgroup for percentage total body surface area (TBSA) burned.
(a, b) Acute kidney injury (AKI). (c, d) Mortality. *Significant difference (P < 0.05) between groups.
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late death (Table 4(b)) the significant cut-off values for
plasma NGAL ranged from 100.5 to 146.5 ng/mL within
6 h of admission. Additionally, the cut-off values for urine
NGAL ranged from 15.6 to 20.1 ng/mL within 6 h of
admission.
Changes in plasma and urine NGAL levels with respect to
burn size and inhalation injury
The presence of inhalation injuries and the % TBSA
burned are the most powerful factors with which to
determine the injury severity in major-burn patients.
Therefore, we investigated the differences in the plasma
and urine NGAL levels with respect to the injury sever-
ity as determined by the % TBSA burned and the pres-
ence of inhalation injuries. According to our data, as the
% TBSA burned increased (larger burn-size group: 50 to
100% TBSA burned), both the mean plasma NGAL and
urine NGAL levels significantly increased within 12 h of
admission in both patients with and without inhalation
injuries (Figure 3).As shown in Figure 3, we observed gross difference in
plasma and urine NGAL with inhalation injury. In the
patients with TBSA burned between 20 and 49%, mean
plasma NGAL was 116.1 in the patients without inhal-
ation injury and 176.8 in those with inhalation injury
(P = 0.018). Also, mean urine NGAL in these patients
was significantly different with inhalation injury (49.4 with-
out inhalation injury versus 172.4 with inhalation in-
jury, P = 0.048). In the patients with TBSA burned
between 50 and 100%, there were significant differences
in plasma NGAL (211.1 without inhalation injury versus
267.5 with inhalation injury, P = 0.013) and urine NGAL
(227.0 without inhalation injury versus 556.3 with in-
halation injury, P = 0.000) by the presence of inhalation
injury.
After classifying the patients into subgroups according to
50% TBSA burned, we investigated changes in the plasma
and urine NGAL levels with respect to AKI and mortality.
In both groups (< 50% and ≥ 50% TBSA burned), the plasma
NGAL levels differed significantly with respect to AKI
(no AKI versus AKI; < 50% burned, 103.0 versus 169.1 ng/mL,
Table 3 Performance characteristics of biochemical
markers with for predicting acute kidney injury (AKI)
(a) Performance characteristics of biochemical markers for
predicting early AKI development (n =66)
Time from admission
0 h 3 h 6 h 12 h 24 h 48 h
AUC of serum creatinine 0.816* 0.823* 0.881* 0.988* 0.987* 0.898*
Cut-off value, mg/dL 0.85 0.85 0.85 1.05 1.15 0.95
Sensitivity 0.710 0.645 0.700 0.926 0.913 0.778
Specificity 0.706 0743 0.824 0.971 1.000 0.853
AUC of serum cystatin C 0.615 0.54 0.605 0.746* 0.731* 0.619
Cut-off value, mg/L 0.70 0.75
Sensitivity 0.704 0.652
Specificity 0.500 0.618
AUC of plasma NGAL 0.832* 0.905* 0.926* 0.847* 0.818* 0.705*
Cut-off value, ng/mL 100.5 172.0 159.0 175.5 185.5 144.0
Sensitivity 0.806 0.806 0.900 0.815 0.739 0.667
Specificity 0.735 0.800 0.794 0.765 0.912 0.647
AUC of urine NGAL 0.921* 0.927* 0.896* 0.813* 0.914* 0.802*
Cut-off value, ng/mL 36.6 31.9 26.8 26.8 42.3 52.9
Sensitivity 0.871 0.871 0.800 0.815 0.870 0.722
Specificity 0.824 0.829 0.853 0.765 0.824 0.706
(b) Performance characteristics of biochemical markers for
predicting late AKI development (n = 59)
Time from admission
0 h 3 h 6 h 12 h 24 h 48 h
AUC of serum creatinine 0.581 0.55 0.609 0.605 0.660* 0.625
Cut-off value, mg/dL 0.85
Sensitivity 0.739
Specificity 0.676
AUC of serum cystatin C 0.488 0.437 0.545 0.491 0.513 0.444
AUC of plasma NGAL 0.682* 0.658* 0.670* 0.605 0.571 0.537
Cut-off value, ng/mL 102.5 100.0 125.0
Sensitivity 0.640 0.583 0.625
Specificity 0.735 0.629 0.676
AUC of urine NGAL 0.692* 0.681* 0.644 0.599 0.598 0.604
Cut-off value, ng/mL 11.95 7.25 8.25
Sensitivity 0.680 0.708 0.625
Specificity 0.647 0.600 0.588
Early AKI, development of AKI within 5 days of injury; late AKI, development of AKI
beyond 5 days after injury; AUC, area under the receiver operating characteristic
curve; NGAL, neutrophil gelatinase-associated lipocalin. *Statistically significant
difference (P < 0.05).
Table 4 Performance characteristics of biochemical
markers for predicting mortality
(a) Performance characteristics of biochemical markers for
predicting early death (n = 67)
Time from admission
0 h 3 h 6 h 12 h 24 h 48 h
AUC of serum creatinine 0.699* 0.697* 0.747* 0.960* 0.941* 0.946*
Cut-off value, mg/dL 0.85 0.85 0.85 1.15 1.65 0.95
Sensitivity 0.588 0.529 0.625 0.923 0.889 1.000
Specificity 0.640 0.640 0.694 0.898 0.980 0.776
AUC of serum cystatin C 0.636 0.501 0.581 0.812* 0.757* 0.811*
Cut-off value(mg/L) 0.80 0.81 0.79
Sensitivity 0.692 0.667 0.750
Specificity 0.694 0.735 0.714
AUC of plasma NGAL 0.848* 0.919* 0.920* 0.892* 0.804* 0.776
Cut-off value, ng/mL 144.5 191.5 181.0 177.0 185.5
Sensitivity 0.824 0.882 0.938 0.923 0.778
Specificity 0.760 0.820 0.837 0.702 0.735
AUC of urine NGAL 0.953* 0.984* 0.967* 0.940* 0.972* 0.939*
Cut-off value, ng/mL 98.9 172.0 45.5 46.0 50.0 83.8
Sensitivity 0.941 0.941 1.000 1.000 1.000 1.000
Specificity 0.840 0.920 0.878 0.796 0.878 0.796
(b) Performance characteristics of biochemical markers for
predicting late death (n = 73)
Time from admission
0 h 3 h 6 h 12 h 24 h 48 h
AUC of serum creatinine 0.595 0.561 0.609 0.625 0.594 0.617
AUC of serum cystatin C 0.478 0.450 0.529 0.503 0.463 0.425
AUC of plasma NGAL 0.650* 0.765* 0.800* 0.629 0.534 0.515
Cut-off value. ng/mL 100.5 126.5 146.5
Sensitivity 0.696 0.739 0.783
Specificity 0.600 0.700 0.714
AUC of urine NGAL 0.734* 0.691* 0.717* 0.607 0.635 0.583
Cut-off value, ng/mL 20.1 16.7 15.6
Sensitivity 0.696 0.696 0.739
Specificity 0.640 0.640 0.673
Early death, non-survivors who developed burn shock despite fluid resuscitation
and died within 3 days of burn injury; late death, mortality due to causes
other than burn shock beyond 3 days; AUC, area under the receiver operating
characteristic curve; NGAL, neutrophil gelatinase-associated lipocalin. *Statistically
significant difference (P < 0.05).
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P < 0.001). Similarly, the urine NGAL levels differed sig-
nificantly with respect to AKI (< 50% burned, 32.1 versus
137.2 ng/mL, P <0.001; ≥ 50% burned, 114.0 versus
438.2 ng/mL, P < 0.001; Figure 4(a), 4(b)). In the samesubgroups, the plasma NGAL levels differed signifi-
cantly with respect to mortality (survivors versus non-
survivors < 50% burned, 116.2 versus 172.9 ng/mL, P =
0.018; ≥ 50% burned, 117.3 versus 201.8 ng/mL, P < 0.001).
Similarly, the urine NGAL levels differed significantly
according to mortality (< 50% burned, 48.5 versus 178.5 ng/
mL, P= 0.049; ≥ 50% burned, 59.9 versus 554.1 ng/mL,
P < 0.001; Figure 4(c), (d)).
Table 5 Multivariate binary logistic regression analysis
for acute kidney injury (AKI) development and mortality
at all time points within 48 h of admission
(a) Multivariate logistic regression analysis of AKI development
95% CI for
odds ratio
Odds ratio P-value Lower Upper
Age >60 years 3.107 12.117
TBSA burned >50% 8.628 0.000* 5.036 14.783
Sex, female 4.199 0.000* 1.940 9.086
Inhalation injury present 3.129 0.000* 1.734 5.647
Serum creatinine >1.1 mg/dL 74.930 0.000* 7.926 708.331
Serum cystatin C >1.1 mg/L 0.150 0.038* 0.025 0.902
Plasma NGAL >153 ng/mL 1.924 0.016* 1.128 3.282
Urine NGAL >131 ng/mL 2.568 0.009* 1.263 5.220
(b) Multivariate logistic regression analysis of mortality
95% CI for
odds ratio
Odds ratio P-value Lower Upper
Age >60 years 23.322 0.000* 9.885 55.023
TBSA burned >50% 25.821 0.000* 12.037 55.389
Sex, female 4.704 0.000* 1.999 11.070
Inhalation injury present 0.923 0.771 0.536 1.588
Serum creatinine >1.1 mg/dL 0.976 0.947 0.480 1.986
Serum cystatin C >1.1 mg/L 2.562 0.137 0.741 8.853
Plasma NGAL >153 ng/mL 1.886 0.023* 1.091 3.259
Urine NGAL >131 ng/mL 7.854 0.000* 3.949 15.622
The biomarker cut-off values were designated according to normal reference
ranges, regardless of our results. The model was based on the univariate analysis,
and no significant interactions between correlated variables were found in a
correlation matrix. *Statistically significant difference (P < 0.05).
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and mortality
A multivariate binary logistic regression analysis for pre-
dicting AKI and mortality was performed and included
the laboratory results at all time points. The age groups
were categorized as either <60 or ≥60 years, the % TBSA
burned groups as <50% or ≥50% of % TBSA burned, the
serum creatinine levels as <1.1 or ≥1.1 mg/dL, the serum
cystatin C levels as <1.1 or ≥1.1 mg/L, the plasma NGAL
levels as <153 or ≥153 ng/mL, and the urine NGAL
levels as <131 or ≥131 ng/mL. The cut-off values of the
biomarkers were determined according to normal refer-
ence ranges from non-hospitalized donors. The analysis
model was based on the univariate analysis, and no sig-
nificant interactions were found between correlated vari-
ables in a correlation matrix.
All variables, including age, % TBSA burned, sex, inhal-
ation injury, serum creatinine levels, serum cystatin C
levels, plasma NGAL levels, and urine NGAL levels,
were independently associated with AKI development(Table 5(a)). Age, sex, % TBSA burned, plasma NGAL
levels, and urine NGAL levels were also independently
associated with mortality. However, inhalation injury,
serum creatinine levels, and serum cystatin C levels were
not independently associated with mortality (Table 5(b)).
Discussion
In this study, we evaluated the diagnostic utility of cysta-
tin C, plasma NGAL, and urine NGAL levels in the early
post-burn period for predicting AKI and mortality in
patients with major burn injuries. In massively burned
patients, the mechanisms associated with early AKI
development and early death differ considerably from
the mechanisms associated with late AKI development
and late death. Therefore, this analysis evaluated both
early and late AKI and both early and late deaths.
All four markers (serum creatinine, serum cystatin C,
plasma NGAL, and urine NGAL) were useful for predict-
ing early AKI and early deaths at nearly all the investigated
time points (Figures 1 and 2). However, the serum creatin-
ine and cystatin C levels rapidly increased only after 12 h
from admission. In contrast, the plasma and urine NGAL
levels had already increased rapidly at the time of admis-
sion. During early AKI in massively burned patients, the
urine NGAL levels first increased, followed by the plasma
NGAL, cystatin C, and serum creatinine levels. Based on
these results, we suspected that serum creatinine could
not be used to diagnose the hyper-acute stage of AKI and
that the plasma and urine NGAL levels were superior bio-
chemical markers for diagnosing AKI. However, in pa-
tients with larger burn-wound surface areas, we observed
increases in both the plasma and urine NGAL levels, as
shown in Figure 3. This indicates that the % TBSA burned
is a possible confounding factor for predictions of early
AKI and early death. However, even in the subgroups
classified according to the % TBSA burned values (<50%
or ≥50%), the plasma and urine NGAL levels differed sig-
nificantly with respect to AKI and mortality (Figure 4).
Only the plasma and urine NGAL levels exhibited stat-
istical significance for predicting late AKI and late deaths
within 6 h of admission. However, given these results,
we cannot confirm that the plasma and urine NGAL
levels can distinguish those patients who will develop
late AKI and experience late death from those who will
not develop AKI and will survive. The mean % TBSA
burned values were 38.4% ± 14.1% in the no-AKI group
versus 61.5% ± 19.2% in the late-AKI group and 41.9% ±
15.2% in the survivor group versus 65.7% ± 18.4% in the
late-death group. All of the AUCs for the plasma and
urine NGAL levels within 6 h were <0.7 for late AKI
and late death. Therefore, we cannot confirm that the
plasma and urine NGAL levels can predict late AKI de-
velopment and late death in massively burned patients
because of the possible confounding effect of the burn
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siderably lower than the normal reference range (Tables 3
and 4), suggesting that patients with intact renal function
experienced significant diuresis due to a massive fluid re-
suscitation. Therefore, these cut-off values are not neces-
sarily transferable to other situations.
In a multivariate logistic regression analysis that in-
cluded the laboratory results at all time points, all the
variables - including age, % TBSA burned, sex, presence of
inhalation injury, and serum creatinine, serum cystatin C,
plasma NGAL, and urine NGAL levels - were independ-
ently associated with AKI development (Table 5(a)). Age,
sex, % TBSA burned, plasma NGAL levels, and urine
NGAL levels were also independently associated with
mortality. However, inhalation injury, serum creatinine
levels, and serum cystatin C levels were not independently
associated with mortality (Table 5(b)). Based on these re-
sults, we can confirm that the plasma and urine NGAL
levels in the early post-burn period can predict AKI and
mortality in major-burn patients. Our results are consist-
ent with two recent reports demonstrating NGAL as an
indicator for AKI in burn patients [14,15].
A limitation of this study is that early AKI was already
present at admission, and therefore, the utility of refin-
ing the AKI diagnosis is unclear. The very good diagnos-
tic performance of the creatinine levels at 12 to 24 h is
unsurprising, as this test represents the gold standard
for early AKI diagnosis. However, the poor gold standard
for AKI assessment limits the performance characteris-
tics of even the best biomarkers.
Conclusions
Massively burned patients who maintain high plasma
and urine NGAL levels until 48 h after admission are at
risk of early AKI development and early mortality with
burn shock. However, the plasma and urine NGAL levels
in the early post-burn period failed to predict late AKI
development and late death in this study. Nonethe-
less, the plasma and urine NGAL levels within 48 h
of admission were independently associated with AKI
development and mortality. In a future study, we should
further investigate the diagnostic efficacy of plasma
and urine NGAL levels in massively burned patients
during the late post-burn period with regard to AKI
and mortality.
Key messages
 In massively burned patients, the plasma and urine
NGAL levels increased rapidly during early AKI,
followed by the cystatin C and serum creatinine
levels.
 Increased plasma and urine NGAL levels in the
early post-burn period were associated with earlyAKI and burn shock mortality but failed to predict
late AKI and non-burn shock mortality.
 The plasma and urine NGAL levels increased
significantly in patients with larger burn-wound
surface areas.
 The plasma and urine NGAL levels within 48 h of
admission were independently associated with AKI
development and mortality.
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